Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Current Liabilities (2020 - 2025)

Rani Therapeutics Holdings has reported Total Current Liabilities over the past 6 years, most recently at $12.7 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $12.7 million for Q4 2025, down 36.31% from a year ago — trailing twelve months through Dec 2025 was $12.7 million (down 36.31% YoY), and the annual figure for FY2025 was $12.7 million, down 36.31%.
  • Total Current Liabilities for Q4 2025 was $12.7 million at Rani Therapeutics Holdings, down from $19.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for RANI hit a ceiling of $20.6 million in Q2 2025 and a floor of $2.6 million in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $8.0 million (2023), compared with a mean of $10.9 million.
  • Biggest five-year swings in Total Current Liabilities: crashed 50.26% in 2021 and later soared 189.12% in 2024.
  • Rani Therapeutics Holdings' Total Current Liabilities stood at $2.6 million in 2021, then surged by 82.39% to $4.8 million in 2022, then surged by 65.92% to $8.0 million in 2023, then soared by 148.98% to $19.9 million in 2024, then crashed by 36.31% to $12.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $12.7 million (Q4 2025), $19.1 million (Q3 2025), and $20.6 million (Q2 2025) per Business Quant data.